Presence of Tissue Transglutaminase in Granular Endoplasmic Reticulum is Characteristic of Melanized Neurons in Parkinson's Disease Brain

@article{Wilhelmus2011PresenceOT,
  title={Presence of Tissue Transglutaminase in Granular Endoplasmic Reticulum is Characteristic of Melanized Neurons in Parkinson's Disease Brain},
  author={Micha M. M. Wilhelmus and Robin Verhaar and Gerda Andringa and John G. J. M. Bol and Patrick Cras and Ling Shan and Jeroen J. M. Hoozemans and Benjamin Drukarch},
  journal={Brain Pathology},
  year={2011},
  volume={21}
}
Parkinson's disease (PD) is characterized by the accumulation of α‐synuclein aggregates and degeneration of melanized neurons. The tissue transglutaminase (tTG) enzyme catalyzes molecular protein cross‐linking. In PD brain, tTG‐induced cross‐links have been identified in α‐synuclein monomers, oligomers and α‐synuclein aggregates. However, whether tTG and α‐synuclein occur together in PD affected neurons remains to be established. Interestingly, using immunohistochemistry, we observed a granular… Expand
Increase in endoplasmic reticulum-associated tissue transglutaminase and enzymatic activation in a cellular model of Parkinson's disease
TLDR
The data provide strong evidence for a, so far unrecognized, localization of t TG at the ER, at least in catecholaminergic neurons, and suggests that in PD activation of tTG may have a direct impact on ER function, in particular via post-translational modification of ER membrane proteins. Expand
Transglutaminase 2 exacerbates α‐synuclein toxicity in mice and yeast
TLDR
It is demonstrated that transglutaminase 2 promotes the aggregation of α‐synuclein in vivo and that this is associated with aggravated toxicity ofα‐syn nuclein and its downstream neuropathologic consequences. Expand
The role of α-synuclein in neurodegeneration — An update
TLDR
Investigation in the early aggregation pathway, aberrant cellular effects, or secretion of α-synuclein might be targets for neuroprotection and disease-modifying therapy, and emerging evidence suggests that prionlike induction and seeding of β-pleated aggregation could lead to the spread of the pathology and disease progression. Expand
New insight into transglutaminase 2 and link to neurodegenerative diseases
TLDR
Recent advances in TG2 biochemistry, several mechanisms of molecular regulation and pleotropic signaling functions, and the presumed role of TG2 in the progression of many NDDs are discussed. Expand
Transglutaminase 1 and its regulator tazarotene‐induced gene 3 localize to neuronal tau inclusions in tauopathies
TLDR
It is concluded that TG1‐catalysed cross‐linking, regulated by TIG3, might play an important role in the formation of neuronal tau inclusions in PSP, FTDP‐17T, and PiD brain. Expand
Transglutaminase 2: biology, relevance to neurodegenerative diseases and therapeutic implications.
TLDR
The biochemistry of TG2, its various physiologic functions and current understanding about its role in degenerative diseases of the brain are discussed and the different approaches to designing TG2 inhibitors that could be developed as potential disease-modifying therapies are described. Expand
5‐S‐cysteinyldopamine neurotoxicity: Influence on the expression of α‐synuclein and ERp57 in cellular and animal models of Parkinson's disease
TLDR
The present work provides a solid background sustaining the hypothesis that CysDA is involved in parkinsonian neurodegeneration by inducing extensive oxidative stress and protein aggregation. Expand
Endoplasmic reticulum-stress and protein aggregation in Parkinson's disease: elucidating the contribution of tissue transglutaminase
Transamidation of α-synuclein by the Ca2+-dependent enzyme tissue transglutaminase (tTG, EC 2.3.2.13) is implicated in Parkinson’s disease (PD). tTG may therefore offer a novel therapeutic target toExpand
Tissue transglutaminase cross-links beclin 1 and regulates autophagy in MPP+-treated human SH-SY5Y cells
TLDR
These data provide first evidence for a role of tTG-mediated regulation of beclin 1 and autophagy in MPP(+)-treated human SH-SY5Y cells. Expand
Catalytically active tissue transglutaminase colocalises with Aβ pathology in Alzheimer’s disease mouse models
TLDR
Association of both tTG and in situ active tTG with Aβ plaques and vascular Aβ, in early and late stages of Aβ deposition is found, providing evidence for an early role of tTG in Aβ pathology. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 59 REFERENCES
Tissue transglutaminase catalyzes the formation of alpha‐synuclein crosslinks in Parkinson's disease
TLDR
Much of the α‐synuclein monomer in PD nigra is crosslinked by tTG and thus may be functionally impaired, and this modification appears to be an early step in PD pathogenesis, preceding the aggregation of α‐ synuclein in Lewy bodies. Expand
Tissue transglutaminase-induced aggregation of α-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies
TLDR
Findings suggest that tTGase activity leads to α-synuclein aggregation to form Lewy bodies and perhaps contributes to neurodegeneration. Expand
Tissue Transglutaminase Is Increased in Huntington's Disease Brain
TLDR
Tissue transglutaminase is elevated in HD brain and may play a role in the disease process, and quantitative analysis of immunoblots and immunohistochemical and biochemical methods clearly indicate. Expand
Activation of the unfolded protein response in Parkinson's disease.
TLDR
Data show that the UPR is activated in PD and that UPR activation is closely associated with the accumulation and aggregation of alpha-synuclein. Expand
Neuropathology of synuclein aggregates
TLDR
Clinicians believe that clarification of the mechanism of synuclein aggregation could augment efforts to develop novel and more effective therapies for many neurodegenerative disorders. Expand
Transglutaminases and Transglutaminase‐Catalyzed Cross‐Links Colocalize with the Pathological Lesions in Alzheimer's Disease Brain
TLDR
It is concluded that these TGs demonstrate cross‐linking activity in AD lesions, which suggests that both TG1 and TG2 are likely involved in the protein aggregation processes underlying the formation of SPs, CAA and/or NFTs in AD brain. Expand
Tissue transglutaminase: a novel pharmacological target in preventing toxic protein aggregation in neurodegenerative diseases.
TLDR
The role of tTG in the initiation of the aggregation process of self-interacting proteins in these diseases is focused on, and the notion that tTG might be an attractive novel target for treatment of neurodegenerative diseases is promoted. Expand
Expanding insights on the involvement of endoplasmic reticulum stress in Parkinson's disease.
TLDR
The authors review the emerging role of ER stress in PD and related disorders, and highlight current knowledge that may reveal novel insight into disease mechanisms and help to provide novel avenues to potential therapies. Expand
Transglutaminase Cross‐Links in Intranuclear Inclusions in Huntington Disease
TLDR
The hypothesis that transglutaminase catalyzed cross-linking of mutant huntingtin is involved in the formation and/or stabilization of huntingtin protein aggregates in HD is supported. Expand
Tissue transglutaminase modulates α‐synuclein oligomerization
TLDR
It is proposed that tTG cross‐linking imposes structural constraints on α‐synuclein, preventing the assembly of structured oligomers required for disruption of membranes and for progression into fibrils, which may prevent the progression into pathogenic species. Expand
...
1
2
3
4
5
...